Reduction in Cancer Risk Following Bariatric Surgery

Dr. Rustgi

WeightControl.com Interview with:
Vinod K Rustgi, MD, MBA
Professor of Medicine
Clinical Director of Hepatology
Director, Center for Liver Diseases and Liver Masses
Professor of Epidemiology
Professor of Pathology and Laboratory Medicine
New Brunswick, NJ 08901

WeightControl.com:  What is the background for this study?  What are the main findings?

Response: ​Obesity is a burgeoning problem in the USA and globally. It is estimated that over $100 billion are spent in healthcare expenditures each year on those patients with fatty liver disease related to obesity-induced problems.

Lifestyle modification is very difficult to achieve on a sustained basis. Insurance companies have strict criteria for bariatric surgery. Our study of a database of over 100 million lives spanning the years of 2007 to 2017 showed a marked reduction in all malignancies after bariatric surgery and particularly in obesity-related cancers such as colorectal, esophageal, pancreatic, ovarian, uterine, postmenopausal breast and kidney cancers.

Continue reading “Reduction in Cancer Risk Following Bariatric Surgery”

Balloon Device for Weight Loss Linked to Five Deaths

“FDA is issuing an update to alert health care providers of five reports of unanticipated deaths that occurred from 2016 to present in patients with liquid-filled intragastric balloon systems used to treat obesity. Four reports involve the Orbera Intragastric Balloon System, manufactured by Apollo Endo Surgery, and one report involves the ReShape Integrated Dual Balloon System, manufactured by ReShape Medical Inc.

All five reports indicate that patient deaths occurred within a month or less of balloon placement…..”

Please read the FDA report of  08/10/2017  HERE